Table 3.
The median levels of neutralizing antibodies against wild-type SARS-CoV-2 following a primary series of COVID-19 vaccination, stratified by the COVID-19 vaccine regimen.
| Study Participant and Study Visit | CoronaVac/CoronaVac | AZD1222/AZD1222 | CoronaVac/AZD1222 | AZD1222/BNT162b2 | BNT162b2/BNT162b2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median of NAb-WT (IQR, % Inhibition) |
Median Difference a (IQR, % Inhibition) |
P a | Median of NAb-WT (IQR, % Inhibition) |
Median Difference a (IQR, % Inhibition) |
P a | Median of NAb-WT (IQR, % Inhibition) |
Median Difference a (IQR, % Inhibition) |
P a | Median of NAb-WT (IQR, % Inhibition) |
Median Difference a (IQR, % Inhibition) |
P a | Median of NAb-WT (IQR, % Inhibition) |
Median Difference a (IQR, % Inhibition) |
P a | |
| All participants | |||||||||||||||
| Pre-prime visit | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Post-prime visit | 2.7 (0–10.4) |
2.4 (0–10.3) |
<0.001 | 36.1 (16.6–58.6) |
36.1 (36.1–58.2) |
<0.001 | 0 (0.0–3.8) |
0 (0–3.8) |
<0.001 | 38.1 (17.7–63.9) |
37.6 (17.4–62.8) |
<0.001 | 58.8 (39.8–71.8) |
58.8 (37.5–71.8) |
<0.001 |
| Post-boost visit | 59.9 (42.5–75.2) |
51.6 (35.6–68.3) |
<0.001 | 76.7 * (54.9–92.3) |
31.7 (9.5–53.3) |
<0.001 | 91.9 * (76.6–97.6) |
85.9 (72.3–93.4) |
<0.001 | 98.8 * (97.6–99.2) |
59.4 (33.4–77.1) |
<0.001 | 98.4 * (96.5–99.1) |
40.5 (26.8–58.4) |
<0.001 |
| Adults aged < 60 years old | |||||||||||||||
| Pre-prime visit | 0 | 0 |
0 | 0 |
0 | ||||||||||
| Post-prime visit | 2.7 (0–10.4) |
2.4 (0–10.3) |
<0.001 | 45.6 (19.9–64.7) |
43.8 (17.2–64.7) |
<0.001 | 0 (0–4.9) |
0 (0–4.9) |
<0.001 | 47.0 (27.5–68.2) |
45.8 (26.8–68.2) |
<0.001 | 58.8 (39.8–71.8) |
58.8 (37.5–71.8) |
<0.001 |
| Post-boost visit | 59.9 (42.5–75.2) |
51.6 (35.6–68.3) |
<0.001 | 85.4 * (67.0–94.7) |
33.1 (12.7–60.5) |
<0.001 | 94.0 * (83.5–98.6) |
86.4 (77.9–94.0) |
<0.001 | 99.1 * (98.4–99.4) |
51.6 (30.9–69.0) |
<0.001 | 98.4 * (96.5–99.1) |
40.5 (26.8–58.4) |
<0.001 |
| Elderly aged ≥ 60 years old | |||||||||||||||
| Pre-prime visit | - | - | - | 0 | 0 | 0 | - | - | - | ||||||
| Post-prime visit | - | - | - | 34.7 (15.5–53.7) |
34.4 (15.5–53.5) |
<0.001 | 0 (0.0–3.8) |
0 (0–3.8) |
<0.001 | 19.9 (5.4–52.0) |
19.9 (5.4–52.0) |
<0.001 | - | - | - |
| Post-boost visit | - | - | - | 73.3 (47.2–89.9) |
31.0 (9.1–52.5) |
<0.001 | 89.9 † (70.2–95.0) |
81.2 (65.1–91.9) |
<0.001 | 98.0 † (94.9–99.0) |
72.0 (39.2–80.8) |
<0.001 | - | - | - |
Abbreviations: AZD1222 vaccine, the Oxford-AstraZeneca COVID-19 vaccine; BNT162b2, Pfizer-BioNTech vaccine; COVID-19, coronavirus disease 2019; IQR, interquartile range; NAb, neutralizing antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; WT, wild-type SARS-CoV-2; a The Wilcoxon signed-rank test was performed to compare the medians of neutralizing antibody against wild-type SARS-CoV-2 between the indicated visit and the previous visit within each COVID-19 vaccine regimen; * Indicates a significant difference (p < 0.001) of the median of neutralizing antibodies against wild-type SARS-CoV-2 after completion of the primary series of an indicated COVID-19 vaccination, compared with the homologous CoronaVac vaccine regimen, evaluated by the median regression analysis; † Indicates a significant difference (p < 0.01) of the median of neutralizing antibodies against wild-type SARS-CoV-2 after completion of the primary series of an indicated COVID-19 vaccination, compared with the homologous AZD1222 vaccine regimen, evaluated by the median regression analysis.